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Abstract
Background: Infection of nonhuman primates with simian immunodeficiency virus (SIV) or chimeric simian-
human immunodeficiency virus (SHIV) strains is widely used to study lentiviral pathogenesis, antiviral immunity
and the efficacy of AIDS vaccine candidates. SHIV challenges allow assessment of anti-HIV-1 envelope responses
in primates. As such, SHIVs should mimic natural HIV-1 infection in humans and, to address the pandemic, encode
HIV-1 Env components representing major viral subtypes worldwide.
Results: We have developed a panel of clade C R5-tropic SHIVs based upon env of a Zambian pediatric isolate
of HIV-1 clade C, the world's most prevalent HIV-1 subtype. The parental infectious proviral clone, SHIV-1157i,
was rapidly passaged through five rhesus monkeys. After AIDS developed in the first animal at week 123 post-
inoculation, infected blood was infused into a sixth monkey. Virus reisolated at this late stage was still exclusively
R5 tropic and mucosally transmissible. Here we describe the long-term follow-up of this initial cohort of six
monkeys. Two have remained non-progressors, whereas the other four gradually progressed to AIDS within
123–270 weeks post-exposure. Two progressors succumbed to opportunistic infections, including a case of SV40
encephalitis.
Conclusion:  These data document the disease progression induced by the first mucosally transmissible,
pathogenic R5 non-clade B SHIV and suggest that SHIV-1157i-derived viruses, including the late-stage, highly
replication-competent SHIV-1157ipd3N4 previously described (Song et al., 2006), display biological
characteristics that mirror those of HIV-1 clade C and support their expanded use for AIDS vaccine studies in
nonhuman primates.
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Background
Animal models of viral diseases have contributed signifi-
cantly towards our understanding of virus life cycles,
routes of transmission and pathologic sequelae following
infection. In the case of HIV, macaque models are used to
mimic HIV transmission and disease progression in
humans, using either simian immunodeficiency virus
(SIV) or chimeric simian-human immunodeficiency virus
(SHIV) strains that can be tracked prospectively by mark-
ers such as plasma viremia levels and loss of peripheral
blood CD4+ T cells. Nonhuman primate models of HIV
infection are also used to study the efficacy of candidate
vaccines and to evaluate innate and adaptive immune
responses to the virus. However, to obtain biologically rel-
evant results from animal models, the challenge viruses
used should mirror naturally occurring HIV infection in
humans and therefore should: 1) be highly replication
competent, 2) be mucosally transmissible and use the
CCR5 coreceptor for target cell entry, as 90% of all HIV
transmissions occur mucosally and almost always involve
R5 viruses [1-7], 3) induce disease in a pattern of acute
and chronic phases approximating natural disease pro-
gression in HIV-infected patients, and 4) cause a relatively
slow onset of AIDS.
We developed a clade C SHIV (SHIV-C), termed SHIV-
1157i, which encodes an envelope derived from a Zam-
bian infant recently infected with clade C HIV (HIV-C)
[8]. SHIV-1157i was then adapted to rhesus monkeys by
rapid animal-to-animal passage. Here we describe clinical
data from the initial cohort of six animals exposed to the
virus during the course of serial viral passage. We show
that infection of macaques with either SHIV-1157i or with
passaged virus leads to depletion of both memory and
total CD4+ T cells, resulting in AIDS and multiple oppor-
tunistic infections in some monkeys. Importantly, these
hallmarks of primate immunodeficiency virus virulence
arose gradually, reflecting the disease progression rate
seen in HIV-infected humans.
Methods
Virus isolate
The origin, cloning and nomenclature of SHIV-1157i,
SHIV-1157ipd and SHIV-1157ipd3N4 is described else-
where [8]. Briefly, SHIV-1157i is an infectious molecular
clone, SHIV-1157ip designates the passaged virus, a bio-
logical isolate derived from monkey RKl-8 (passage 4).
Animals and animal care
Six rhesus monkeys (Macaca mulatta) of Indian origin
were used for this study. The first recipient was inoculated
i.v. with 6 ml cell-free supernatant from 293T cells trans-
fected with the infectious molecular clone, SHIV-1157i.
Plasma vRNA loads were measured weekly; if week 1
loads were ≥ 104 copies/ml, 1 ml of infected blood was
transfused at week 2 post-inoculation to the next animal.
In each case, peak viremia occurred at week 2. Monkey
RBg-9 was inoculated i.v. one month after onset of AIDS
in RPn-8 (week 123 p.i.) by transfusing 10 ml of blood.
All animals were kept according to National Institutes of
Health guidelines on the care and use of laboratory ani-
mals at the Yerkes National Primate Research Center
(Emory University, Atlanta, GA). The facility is fully
accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care International. All exper-
iments were approved by the Animal Care and Use
Committees of the Yerkes National Primate Research
Center and the Dana-Farber Cancer Institute.
Plasma vRNA loads
RNA was isolated from plasma using QiaAmp Viral Mini
Kit (Qiagen), and vRNA loads were measured by quanti-
tative reverse transcriptase PCR (RT-PCR) for SIV gag
sequences [9]. The detection limit was 50 viral RNA cop-
ies/ml of plasma.
Gross pathology
A complete necropsy was performed on RKl-8 and RPn-8
after death or following euthanasia. Representative tissue
from brain, heart, lungs, liver, kidneys, spleen, lymph
nodes, bone marrow and gastrointestinal tract were col-
lected in 10% neutral buffered formalin.
Histology
After fixation the tissue samples were sectioned, processed
and embedded in paraffin. For histopathological exami-
nation, thin sections (5 μm) of paraffin-embedded tissue
were stained with hematoxylin and eosin (H&E).
Immunohistochemistry (IHC)
IHC was performed for simian virus 40 (SV40) and rhesus
lymphocryptovirus (LCV), an Epstein-Barr virus (EBV)-
related herpesvirus of rhesus monkeys, using a commer-
cial kit (ABC Elite, Vector Laboratories, Burlingame, CA)
and monoclonal antibodies (mAbs) that recognize either
SV40 large T-antigen (Calbiochem, San Diego, CA) or EBV
encoded nuclear antigen 2 (EBNA-2, Leica Microsystems,
Bannockburn IL), respectively. Formalin-fixed, paraffin-
embedded (FFPE) sections of brain (for SV40) and tongue
(for EBNA-2) were deparaffinized in xylene and rehy-
drated through graded ethanol to distilled water. Endog-
enous peroxidase activity was blocked by incubation in
3% H2O2, and antigen retrieval was accomplished by
microwaving sections for 20 minutes in citrate buffer
(Dako Corp., Carpinteria, CA). Sections were incubated
for 30 minutes at room temperature with primary anti-
bodies, and reacted sequentially with appropriate bioti-
nylated secondary antibodies and horseradish peroxidase-
conjugated avidin DH. Antigen-antibody complex forma-
tion was localized by development in the chromogenicRetrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
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substrate 3, 3'-diaminobenzidine (Dako). Tissue sections
were counterstained in Mayer's hematoxylin (Dako),
cleared, and coverslipped with permanent mounting
medium. Sections of kidney tissue from a rhesus macaque
with SV40 nephritis and sections of oropharyngeal
mucosa infected with rhesus lymphocryptovirus served as
both positive control (when incubated with SV40 or
EBNA-2-specific antibodies, respectively) and negative
control (when incubated with irrelevant, isotype-matched
control immunoglobulins).
In situ hybridization (ISH) for viral pathogens
ISH was performed to localize SV40 DNA and SIV RNA in
FFPE sections of brain. For both reactions, tissue sections
were deparaffinized in xylene and rehydrated in graded
ethanol to diethyl pyrocarbonate (Sigma-Aldrich, St.
Louis, MO) treated water. Endogenous alkaline phos-
phatase activity was blocked with levamisole (Sigma), and
tissue sections were hydrolyzed in HCl (Sigma), digested
with proteinase K (Roche Diagnostics, Corp., Indianapo-
lis, IN), and acetylated in acetic anhydride (Sigma). For
SV40 detection, sections were covered with a biotinylated
DNA probe cocktail that spans the entire genome of SV40
(Enzo Life Sciences Inc., Farmingdale, NY), then heated at
95°C for 5 minutes to denature DNA, and hybridized
overnight at 37°C. To detect cells productively infected
with SHIV, brain sections were hybridized overnight at
50°C with a digoxigenin-labeled antisense riboprobe that
spans the entire genome of the SIVmac239 molecular
clone of SIV (Lofstrand Labs, Gaithersburg, MD). For both
ISH reactions, tissue sections were washed extensively the
following day and bound probe was detected by IHC.
Biotinylated SV40 probe was localized with alkaline phos-
phatase-conjugated streptavidin (Dako) and digoxigenin-
labeled SIV probe was detected with alkaline phos-
phatase-conjugated sheep anti-digoxigenin F(ab) frag-
ments (Roche), in both instances using the chromogen
nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl-phos-
phate (NBT/BCIP) (Roche), and sections were counter-
stained with nuclear fast red (Vector Labs). For SV40 ISH
reactions, sections of kidney from a rhesus macaque with
SV40 nephritis served as both positive control (when
incubated with SV40 probe) and negative control (when
reacted with a biotinylated pUC 18 plasmid DNA control
probe). For SIV ISH reactions, sections of lymph node
from a SIVmac239-infected rhesus macaque served as
both positive and negative control (when incubated with
SIV antisense or sense probes, respectively). Additional
negative controls included sections of normal rhesus kid-
ney incubated with SV40 probe and sections of lymph
node from a SIV-negative rhesus macaque incubated with
SIV antisense probe.
Results
Plasma viral loads in monkeys infected with SHIV-1157i or 
passaged virus
The details of the molecular cloning and biological char-
acterization of SHIV-1157i have been previously pub-
lished [8]. For the rapid animal-to-animal passage of
SHIV-1157i, we used five rhesus monkeys (RM); the first
animal was inoculated with 6 ml of cell-free virus
obtained from 293T cells transfected with the infectious
molecular clone, SHIV-1157i (Figure 1). At week 1 post-
inoculation (p.i.), plasma viral RNA (vRNA) loads were
measured and if found to be ≥ 104 copies/ml, 1 ml whole
blood was transfused to the next animal a week later, the
time point of the expected peak viremia (Figure 1).
Plasma vRNA loads, absolute numbers of CD4+ T cells,
percentage CD4+CD29+ memory T cells, and CD4:CD8 T-
cell ratios were monitored longitudinally in peripheral
Serial passage of SHIV-1157i in rhesus monkeys for viral adaptation Figure 1
Serial passage of SHIV-1157i in rhesus monkeys for viral adaptation. The first animal was inoculated i.v. with cell-free 
supernatant from 293T cells transfected with the infectious molecular clone SHIV-1157i; subsequent animals were inoculated 
i.v. through serial blood transfer. The neonatal period comprises birth to one month; infancy the period up to one year, and 
juvenile monkeys are aged between one and five years.Retrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
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blood in all RM. The five RM from the initial virus passage
were divided into two groups: progressors (RPn-8, RTs-7,
RKl-8) and non-progressors (RAo-8, RIl-8) (Figure 2).
Both groups showed an initial peak of viremia within the
first 2 weeks p.i. and seroconverted within 6 weeks. Com-
pared to the first virus recipient, RPn-8, the four subse-
quent RM had peak vRNA loads that were 1–2 logs higher.
After seroconversion, the progressors remained viremic
with plasma vRNA levels ranging from 103 to 5 × 106 cop-
ies/ml, although plasma vRNA levels were occasionally
undetectable in RTs-7 (Figure 2A). In contrast, the non-
progressors controlled viremia after the initial high peak
vRNA levels, and remained aviremic except for occasional
blips that did not exceed 103 copies/ml (Figure 2B). Over-
all, the viral set points of the progressors were 1–4 logs
higher compared to non-progressors; among progressors,
only RTs-7 showed a relatively low vRNA level, with a set-
point of 104 copies or less/ml plasma throughout the lat-
ter portion of the observation period (Fig 2A).
Pathogenicity of passaged virus
In all progressors, peripheral blood CD4+ T-cell depletion
occurred gradually, often first noted in the CD4+CD29+
memory T-cell population (e.g., in RPn-8, Figure 2E). R5
viruses primarily infect and destroy memory CD4+ T cells,
a T-cell subset that expresses the CCR5 co-receptor [10].
The three progressor animals showed slow but persistent
reductions in CD4+ memory T cells (Figure 2E), whereas
the non-progressors showed no such decline (Figure 2F).
The massive loss of CD4+ T cells that accompanies most
untreated HIV infections results in a persistent inversion
of the CD4:CD8 T-cell ratio, which serves as another
important biomarker of lentiviral pathogenicity. In all
progressors, CD4:CD8 T-cell ratios decreased below the
normal pre-inoculation range of 0.7–1.4 for this group
(Figure 2G). In contrast, there was no decrease in the
CD4:CD8 ratios of non-progressors (Figure 2H).
All progressors developed AIDS as defined by persistent
CD4+ T-cell depletion below 200 cells/μl, the Centers for
Disease Control (CDC)-established surveillance case defi-
nition threshold for human AIDS [11] (Figure 2C). The
decrease in peripheral CD4+ T cells observed in the two
non-progressors is consistent with the normal age-related
decline. Of note, both non-progressors (RAo-8 and RIl-8)
were inoculated as neonates. Like human neonates, RM
have CD4+ T-cell counts in the range of 3000 – 4000 cells/
μl at birth, which gradually decline to levels seen typically
in adults (Figure 2D).
Passage of late-stage virus
After monkey RPn-8, the first RM of the SHIV-1157i pas-
sage group, developed AIDS at week 123 p.i (Figure 2C),
we sought to determine whether SHIV-1157i had
acquired a more virulent phenotype in vivo. At week 127
p.i., 10 ml of whole blood was transfused from RPn-8 to
naïve macaque RBg-9. Indeed, peak viremia in the recipi-
ent was approximately 2 logs higher than that induced by
the parental infectious molecular clone in the donor, RPn-
8 (Figures 3A and 3B; and [8]). RBg-9 also experienced a
more rapid depletion of CD4+CD29+ memory T cells in
peripheral blood (week 12, Figure 3F) than RPn-8, and
has progressed to AIDS.
Virus-induced pathology
To determine the extent of disease induced by SHIV-1157i
and passaged progeny virus, complete necropsies with
histopathological evaluations were performed on the two
monkeys (RPn-8 and RKl-8) lost to the complications of
AIDS. Two other monkeys (RTs-7 and RBg-9) are alive
with AIDS at the time of this writing.
RPn-8 consistently maintained fewer than 200 CD4+ T
cells for approximately three years, starting at week 123
p.i. RPn-8 developed intermittent diarrhea that pro-
gressed to watery diarrhea and became unresponsive to
treatment, causing significant weight loss and ultimately
requiring euthanasia at week 280 p.i. At the time of
necropsy, RPn-8 had a CD4+ T-cell count of 10 cells/μl.
RKl-8 had fewer than 200 CD4+ T cells for almost one year
before it died for unknown reasons during exam for acute
onset of ataxia. At the time of death, the animal had a
CD4+ T-cell count of 232 cells/μl.
SHIV-1157i-induced pathogenesis: histopathological 
evaluation
Histopathological evaluation of RPn-8 revealed dissemi-
nated mycobacteriosis, involving the small intestine,
colon, liver, kidneys, lung, bone marrow, and mesenteric,
peripancreatic and periaortic lymph nodes (additional file
1), which was confirmed by acid fast stain (Figure 4E).
The presence of Pneumocystis spp. was noted in the lungs
(additional file 2) and confirmed using Gomori methen-
amine silver stain (Figure 4F). Mycobacteriosis and Pneu-
mocystis pneumonia are typical opportunistic infections
in rhesus macaques with AIDS. Additional lesions in RPn-
8 included focal candidiasis in the oral mucosa, and crypt-
osporidial tracheitis (additional file 3) and nasopharyngi-
tis. Epstein Barr virus-like inclusions were observed in the
mucosal epithelium of the tongue, and immunohisto-
chemistry (IHC) for EBNA 2 provided a definitive diagno-
sis of rhesus lymphocryptovirus infection (Figure 4D and
additional files 4 and 5).
The most prominent histopathological finding in RKl-8
was a multifocal meningoencephalitis attributed to SV40
infection, characterized by prominent mononuclear cell
infiltrates surrounding venules in the meninges and
extensive perivascular cuffing within the brain paren-Retrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
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Plasma vRNA loads and T-cell subsets in rhesus monkeys inoculated with SHIV-1157i or passaged virus Figure 2
Plasma vRNA loads and T-cell subsets in rhesus monkeys inoculated with SHIV-1157i or passaged virus. The 
five animals used for virus adaptation were grouped into progressors and non-progressors. (A, B) Plasma vRNA loads. (C, D) 
Absolute CD4+ T-cell counts. (E, F) Percentage CD4+CD29+ memory T cells. (G, H) CD4:CD8 ratios. The dashed lines in pan-
els C and D designate 200 cells/μl, the case definition threshold for human AIDS. In panels E and F, the dashed line at 10% indi-
cates the lower limit of normal for the percentage of CD4+CD29+ memory T cells. The threshold of detection of vRNA was 50 
copies/ml. †, euthanasia due to AIDS-related disease (RPn-8) or unrelated reasons (RIl-8); monkey RKl-8 died during blood col-
lection.Retrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
Page 6 of 12
(page number not for citation purposes)
chyma (Figures 4A, additional file 6A). Other CNS find-
ings included focal rarefaction of the cerebral white matter
associated with inflammation (additional file 6B). In situ
hybridization (ISH) for SIV gag and pol RNA failed to
identify productively infected cells within inflammatory
infiltrates, which suggested that the encephalitis was not a
direct result of SHIV infection but rather was secondary to
an opportunistic agent. Determination of proviral DNA
load by PCR confirmed a low level of SHIV infection of
the brain tissues (data not shown). Although viral inclu-
sion bodies were not readily apparent, the presence of oli-
godendrocytes and astrocytes with swollen, euchromatic
nuclei and occasional gemistocytic astrocytes within and
surrounding the inflammatory lesions were suggestive of
SV40 infection. IHC for SV40 large T antigen and ISH for
SV40 DNA revealed the presence of large numbers of
SV40-infected cells within encephalitic lesions and in the
normal tissue surrounding lesions, providing confirma-
tion of SV40 meningoencephalitis (Figure 4B, 4C and
additional file 7).
Disease progression caused by the parental and late viruses Figure 3
Disease progression caused by the parental and late viruses. Comparison of RPn-8 inoculated with SHIV-1157i and 
RBg-9 inoculated with the late virus (after AIDS had developed in monkey RPn-8). Panels show plasma vRNA loads (A, B), 
absolute CD4+ T cells (C, D) and percentage CD4+CD29+ memory T cells (E, F).Retrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
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Figure 4
Histological examination of RKl-8 (Panel A-C) and RPn-8 (Panel D-F). (A) Meningoencephalitis in RKl-8 brain, char-
acterized by perivascular infiltrates ("perivascular cuffs") of mononuclear leukocytes (arrows) within the cerebral parenchyma, 
typical of viral encephalitis. Rarefaction of the white matter, consistent with demyelination, is also present (yellow arrow). (B, 
C) SV40 meningoencephalitis in RKl-8. SV40-positive cells were localized in the same regions by immunohistochemistry (IHC) 
(B) and in situ hybridization (ISH) (C). IHC for large T antigen shows SV40 positive cells (arrows) adjacent to a vessel (V) sur-
rounded by inflammatory cells. SV40 DNA is localized within cells by ISH (blue NBT/BCIP chromogen) in a serial section of 
panel B. (D) Rhesus lymphocryptovirus infection. IHC for EBNA 2 on serial section of tongue shown in additional file 5A, dem-
onstrating widespread localization of EBNA 2 protein expression in nuclei of mucosal epithelial cells (brown chromogen). (E) 
Mycobacterial infection in RPn-8. Acid fast stain of mesenteric lymph node reveals large numbers of mycobacteria-filled macro-
phages (magenta color; arrows). (F) Pneumocystis pneumonia in RPn-8. Section of lung stained by Gomori methenamine silver 
(GMS) technique to localize fungal organisms. Pneumocystis organisms (arrows) within the foamy exudate appear as crescent-
shaped or folded spheres.Retrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
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Other histopathological findings in macaque RKl-8
included lentiviral arteriopathy, as evidenced by intimal
thickening and fibrosis, luminal narrowing, occasional
vasculitis, and rare thrombosis of the periaortic vascula-
ture, as well as in medium and large arteries in the kid-
neys, colon (additional files 8 and 9), and lungs. In
addition, there was follicular depletion and lymphoid
atrophy of secondary lymphoid organs (spleen and
lymph nodes), and cryptosporidial enteritis, confirmed by
the presence of moderate numbers of cryptosporidial
organisms within small intestinal crypts.
Envelope evolution of SHIV-1157i
We analyzed sequences of the original virus clone (SHIV-
1157i), the virus re-isolated week 6 p.i. from RKl-8 after
passage through five rhesus monkeys (SHIV-1157ip), and
the virus re-isolated from RPn-8 four weeks after the onset
of disease (SHIV-1157ipd3N4). The data, partially pub-
lished by Song et al. [8], show common amino acid sub-
stitutions in the variable loops of gp120 (V1-V4) for
SHIV-1157ipd3N4 as well as an amino acid substitution
for N295, which is part of the 2G12 epitope rendering this
virus less sensitive for 2G12-mediated neutralization (Fig-
Sequences analysis of SHIVs Figure 5
Sequences analysis of SHIVs. Alignment of Env amino acid sequences SHIV-1157i, SHIV-1157ip and SHIV-1157ipd3N4. 
Prominent domains of gp160 are highlighted in color and labeled. V1-V5 = variable loops V1-V5 gp120; IDR = immunodomi-
nant region gp41; MSD1-MSD3 = membrane spanning domains 1–3.Retrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
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ure 5). Additionally, SHIV-1157ip and SHIV-1157ipd3N4
have an insertion in the intracellular part of gp41 (Figure
5).
Discussion
Here we describe a SHIV which: 1) encodes env  of a
recently transmitted, pediatric HIV clade C strain from
Zambia; 2) is highly replication competent as shown by
long-term follow up of an initial cohort of macaques used
to adapt the infectious molecular clone of this SHIV-C,
SHIV-1157i; 3) uses R5 as coreceptor for viral entry [8];
and 4) is pathogenic with gradual disease progression to
AIDS.
It is known that 90% of all HIV infections among humans
occur through mucosal transmissions. SHIV-1157ip, the
animal-passaged, biological isolate derived from the orig-
inal SHIV-1157i, was shown to be mucosally transmissi-
ble. This isolate was used as oral challenge virus in a recent
vaccine study [12], which was preceded by a formal titra-
tion through the oral route to determine the 50% animal
infectious dose (AID50) of the SHIV-1157ip challenge
stock.
The parental infectious molecular clone, SHIV-1157i,
encodes env of a recently transmitted HIV-C. Our rapid
animal-to-animal adaptation was designed to avoid nAb-
mediated selection pressure by transferring virus at peak
viremia from one donor to the next recipient. Since peak
viremia occurs at two weeks p.i., nAbs will not yet have
formed and thus, our adaptation strategy likely preserved
the important structural characteristics of the recently
transmitted HIV-C Env 1157i molecule. Interestingly,
recently transmitted HIV-C was shown to be remarkably
sensitive to neutralization in a study that prospectively
followed HIV-discordant heterosexual couples [13]. Virus
isolated from the newly infected partner was significantly
more neutralization sensitive than contemporaneous
virus isolated from the infected source person [13]. More-
over, the newly transmitted HIV-C gp120 molecules had
significantly shorter amino acid lengths in the V1 to V4
region as well as fewer potential N-linked glycoprotein
sites compared to the HIV-C quasispecies circulating in
the source persons [13]. The V1 to V4 amino acid lengths
in viruses of such newly HIV-C-infected Zambian individ-
uals was also significantly shorter compared to virus from
individuals with newly acquired HIV-B infection [14].
These data imply that recently transmitted HIV-C gp160
exist in a more open configuration and may expose neu-
tralizing epitopes which become inaccessible during
chronic infection. These special characteristics of recently
transmitted HIV-C Env may have implications for anti-
HIV-C vaccine design. Whether these observations hold
for recently transmitted virus strains of other clades and
for other transmission routes has been questioned [14-
16]. Of note, however, shorter gp120 V1 to V2 amino acid
lengths in recently transmitted HIV clade A (HIV-A)
sequences in comparison to HIV-A sequences in the Los
Alamos database were also reported [17]. Consequently,
SHIV-1157ip with its recently transmitted HIV-C Env
insert may turn out to be a valuable tool to assess vaccine
efficacy in primate model studies.
Late stage SIV has been described as more virulent com-
pared to early forms [18]. To test whether a similar
increase in virulence would occur with SHIV-C, we per-
formed a late blood transfer into monkey recipient RBg-9
after AIDS had developed in the first inoculated monkey,
RPn-8, in which the late-stage virus, SHIV-1157ipd, had
evolved during 127 weeks of continuous viremia. SHIV-
1157ipd appeared to be more virulent than the early
SHIV-C form by inducing higher peak vRNA loads and
depleting the CD4+CD29+ memory T-cell population in
RBg-9 within a few weeks only. The full pathogenic poten-
tial of the late-stage virus was demonstrated by total CD4+
T cells in RBg-9 dropping below 200 cells/μl blood. Nota-
bly, SHIV-1157ipd3N4 [8] was derived directly from this
late-stage biological isolate SHIV-1157ipd; the infectious
molecular clone SHIV-1157ipd3N4 was engineered to
encode additional NF-κB sites in the LTRs to increase rep-
licative capacity. SHIV-1157ipd3N4 retained its R5 tro-
pism, is mucosally transmissible, is pathogenic and causes
AIDS, and has also already been used in vaccine studies by
our group ([12], unpublished data).
Although SHIV-1157ip is not the first non-clade B R5
SHIV [19-22], SHIV-1157i and its progeny have certain
features which are not shared by other chimeras. None of
the previously described non-clade B SHIVs was shown to
be mucosally transmissible and to cause AIDS in rhesus
macaques. Of note, some of the non-clade B chimeras use
CXCR4 as coreceptor or are dual tropic (reviewed in [23]).
We and others [23,24] have suggested that primate mod-
els of HIV infections should not only reflect key aspects of
HIV transmission among humans, but also mirror the tar-
get cell specificity during acute infection and the natural,
gradual disease progression seen in HIV-infected humans.
Key findings of Nishimura et al. [25] showed that acute
infections of R5 and X4 viruses differ in targeting separate
CD4+ T-cell subsets, resulting in distinct patterns of subse-
quent CD4+  T-cell depletion. R5-tropic SIVmac239  or
SIVsmE543 strains preferentially target and destroy CCR5+
memory CD4+ T cells. After acute viremia, SIV-infected
monkeys progressed to AIDS over several months and
showed selective depletion of memory cells with a com-
plete loss at time of death. In contrast, SHIVDH12R or
SHIVKU1 use CXCR4 for infection, which is preferentially
expressed on naïve CD4+ T cells. SHIV89.6P, one of the
most widely used strains in monkey models, is dual tropicRetrovirology 2008, 5:94 http://www.retrovirology.com/content/5/1/94
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in vitro but acts like an X4 virus in vivo [26]. SHIV89.6P as
well as X4 SHIV strains induce massive elimination of
naïve CD4+ T cells, leading to a rapid and mostly irrevers-
ible loss of peripheral blood CD4+ T cells within approxi-
mately two weeks post-inoculation. This acute onset of
severe T-cell depletion, which is also seen with the related
SHIV89.6PD [27], does not reflect the clinical course of
HIV infection seen in humans. In contrast, the gradual dis-
ease progression caused by our R5-tropic SHIV-1157i-
derived viruses is more reflective of HIV disease progres-
sion in humans.
Several R5-tropic SHIV-B strains have been described [28-
30] based upon HIVSF162 or HIVBa-L env inserts, giving rise
to SHIVSF162P3/SHIVSF162P4  and SHIVBa-L  [28,29].
SHIVSF162P3 and SHIVSF162P4 differ in their monkey passage
histories and in their neutralization sensitivities, with P4
classified as Tier 1 virus and P3 as a more difficult to neu-
tralize Tier 2 strain (David Montefiori, personal commu-
nication). SHIVSF162P3 induces gradual CD4+ T-cell loss
and causes AIDS in some but not all rhesus macaques
[31]. Recently, Pahar et al. [32] using vaginal SHIVSF162P3
challenge observed control of viremia with modest deple-
tion of the memory CD4+ T cell subset; however, these
animals were followed only until day 84 p.i. Overall,
SHIVSF162P3 induced progressive disease leading to AIDS
in 6 out of 11 rhesus monkeys with systemic infection
after intravaginal challenge [33]; the time to development
of AIDS varied from 5.5 weeks to 104 weeks p.i
SHIVSF162P3 was adapted to rhesus monkeys cumulatively
over a time span of 26 weeks. In contrast, the animals
described in our cohort were infected with an R5 SHIV-C
that was in the process of being adapted. Even virus reiso-
lated from the last recipient in the serial transfer, monkey
RKl-8, replicated only a total of 14 weeks in rhesus
macaques. Not surprisingly therefore, SHIV-1157i (the
parental virus in monkey RPn-8) and its progeny induced
progression to AIDS that was somewhat slower compared
to SHIVSF162P3. Also a consideration is the relatively small
numbers of animals followed long-term with systemic
SHIVSF162P3 or SHIV-1157ip infection. Nevertheless, the
overall biological properties of the two R5 SHIVs seem
similar in outbred rhesus monkeys, with mucosal trans-
missibility and gradual disease progression the key fea-
tures. SHIVSF162P3 has also successfully been used in a
monkey model for mother-to-child transmission to eval-
uate key parameters in perinatal HIV transmission
[34,35].
The related Tier 1 virus, SHIVSF162P4, was used as a chal-
lenge virus in a recent vaccine study using HIV-1 SF162
Env as immunogen; the results showed that antibodies
induced by the homologous vaccine could protect rhesus
macaques from intravaginal challenge [36]. R5-tropic
SHIVBa-L was used in only two short-term vaccine efficacy
studies using intrarectal challenge [37,38]. No informa-
tion has been published as yet regarding the pathogenicity
of SHIVBa-L, whereas SHIVSF162P3  and SHIVSF162P4  are
known to cause progressive disease, including AIDS in a
gradual downhill course.
Recently, the group of Cecilia Cheng-Mayer described for
the first time a coreceptor switch of an R5 SHIV-B,
SHIVSF162P3N [39-41]. Coreceptor switch from CCR5 to
CXCR4 is observed in approximately 50% of HIV-B-
infected humans but only rarely in HIV-C-infected indi-
viduals [39,41,42]. The increase in X4 variants is associ-
ated with rapid CD4+ T-cell loss and progressive disease
[3,43-45]. To reflect HIV transmission and assess AIDS
vaccine efficacy, it is important to examine the underlying
biology for this coreceptor switch. Since this phenome-
non is rare among HIV-C, it will be interesting to test
whether any of our R5 SHIV-C strains have the potential
for coreceptor switch in future studies.
Conclusion
Our long-term follow up of animals infected with SHIV-
1157i and variants thereof document for the first time the
pathogenicity of a R5 clade C SHIV with gradual disease
progression to AIDS manifested by opportunistic infec-
tions typically seen in HIV infections in humans. This sug-
gests that these viruses are biologically relevant tools to
evaluate the efficacy of candidate anti-HIV-C vaccines in
nonhuman primates.
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